Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MDP.TOthis companyMedexus Pharmaceuticals Inc.	CA$5.18	-44.57×	2.06×	1.02×	9.21×	-84.1%	54.8%	5.9%	-2.4%	-4.9%	6.1%	3.7%	0.45×	1.24×	1.12×	1.19×	0.0%	5	1.26	2	C
BNXT.CNBioNxt Solutions Inc.	CA$0.26	-10.76×	-8.07×	0×	-13.49×	-121.0%	0.0%	0.0%	0.0%	75.0%	172.2%	-6.9%	-0.63×	-0.98×	-4.2×	0.05×	0.0%	3	-88.15	2	C
CRDL.TOCardiol Therapeutics Inc.	CA$1.40	-3.36×	6.37×	0×	-2.71×	-83.2%	0.0%	0.0%	0.0%	-189.2%	-190.6%	-21.0%	0.01×	0.62×	0×	4.16×	0.0%	2	5.98	2	C
DB.VDecibel Cannabis Company Inc.	CA$2.04	-21.57×	1.02×	0.56×	-9.27×	-169.4%	15.5%	-15.4%	-2.6%	-4.7%	-16.2%	8.6%	0.71×	-3.39×	-6.57×	1.34×	0.0%	2	1.5	1	C-
IAN.CNiAnthus Capital Holdings, Inc.	CA$0.01	-0.6×	-0.24×	0.17×	47.67×	-1882.1%	32.2%	-10.0%	-27.9%	39.8%	-6.6%	-86.0%	-2.21×	42.83×	-0.68×	0.71×	0.0%	2	-8.47	2	C
INNO.CNInnoCan Pharma Corporation	CA$1.82	-19.52×	3.9×	0.82×	123.74×	-83202.5%	89.9%	-4.7%	-4.2%	-20.1%	54.9%	2.2%	0.17×	-44.28×	-418.33×	7.7×	0.0%	3	-0.95	—	—
Peer median	—	-10.76×	1.02×	0.17×	-2.71×	-169.4%	15.5%	-4.7%	-2.6%	-4.7%	-6.6%	-6.9%	0.01×	-0.98×	-4.2×	1.34×	0.0%	2	-0.95	2	—